Volume 8, Number 5—May 2002
Perspective
Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
Table 2
Challenge of vaccinated monkeys with Ebola virus (EBOV)
NHP Species | Vector | Antigen | Survival/total | Viremic/total | Day of deatha |
---|---|---|---|---|---|
Cynomolgus | Replicon | GP | 0/3 | 3/3 | 6, 6, 7 |
Cynomolgus | Replicon | NP | 0/3 | 3/3 | 6, 6, 7 |
Cynomolgus | Replicon | GP + NP | 0/3 | 3/3 | 6, 6, 7 |
Cynomolgus | Replicon | Influenza HA | 0/3 | 3/3 | 6, 6, 7 |
Cynomolgus | Vaccinia | GP | 0/3 | 3/3 | 6, 7, 7 |
Cynomolgus | Liposome | Inactivated virion | 0/3 | 3/3 | 7, 7, 11 |
Cynomolgus | Inactivated virion | 0/2 | 2/2 | 6, 6 | |
Rhesus | Inactivated virion | 1/2 | 2/2 | 9 | |
Cynomolgus | None | 0/2 | 2/2 | 6, 7 | |
Rhesus | None | 0/2 | 2/2 | 8, 9 |
aNumber of days after challenge with 1,000 PFU of EBOV.
NHP, nonhuman primate; GP, glycoprotein; NP, nucleoprotein.